WO2006024283A2 - Composes et procedes pour traiter, diagnostiquer et pronostiquer des maladies pancreatiques - Google Patents

Composes et procedes pour traiter, diagnostiquer et pronostiquer des maladies pancreatiques Download PDF

Info

Publication number
WO2006024283A2
WO2006024283A2 PCT/DE2005/001527 DE2005001527W WO2006024283A2 WO 2006024283 A2 WO2006024283 A2 WO 2006024283A2 DE 2005001527 W DE2005001527 W DE 2005001527W WO 2006024283 A2 WO2006024283 A2 WO 2006024283A2
Authority
WO
WIPO (PCT)
Prior art keywords
chr
protein
gene
gene product
pancreatic
Prior art date
Application number
PCT/DE2005/001527
Other languages
German (de)
English (en)
Other versions
WO2006024283A3 (fr
Inventor
Günter KLÖPPEL
Jutta Lüttges
Holger Kalthoff
Ole Ammerpohl
Robert Grützmann
Christian Pilarsky
Hans-Detlev Saeger
Ingo Alldinger
Original Assignee
Technische Universität Dresden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universität Dresden filed Critical Technische Universität Dresden
Priority to DE112005002742T priority Critical patent/DE112005002742B4/de
Publication of WO2006024283A2 publication Critical patent/WO2006024283A2/fr
Publication of WO2006024283A3 publication Critical patent/WO2006024283A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the invention relates to nucleic acid sequences and peptides or proteins encoded thereby, as well as the use of sequences derived therefrom for screening substances that bind thereto and the use of substances binding to the nucleic acids and peptides or proteins derived therefrom for diagnosis, prognosis, and for the therapeutic treatment of pancreatic tumors, in particular of the ductal adenocarcinoma of the pancreas.
  • Ductal adenocarcinoma of the pancreas is one of the most common causes of cancer death. In the US, it causes approximately 30,000 deaths each year, and pancreatic cancer ranks 5th among cancer-related causes of death.
  • the diagnosis of pancreatic carcinoma in a patient represents an infertile prognosis.
  • the survival time of all patients with ductal pancreatic carcinoma is on average only 1 year, and only about 4% of the patients survive a period of 5 years.
  • the late diagnosis of these tumors is one reason for the poor survival rate.
  • pancreatic tumors The histological differential diagnosis of pancreatic tumors is often difficult. There are various antibodies used in the pathological routine (eg against cytokeratin 18), but with which it is not always possible to predict the course of the disease. In the investigation of dislocations (metastases) of various carcinomas of the pancreas, biliary tract and gallbladder, as well as the papilla vateri histological assignment to the primary tumor is usually not possible. An assignment of these metastases to the primary tumor is important for the selection of an adapted palliative chemotherapy.
  • pancreatic tumor marker For the early detection, the laboratory differential diagnosis of pancreatic tumors to other pancreatic diseases and the follow-up after surgery, there is so far only one marker, the CA19-9.
  • this tumor marker to be determined in the blood is not very specific and sensitive, i. there are patients with chronic pancreatitis (pancreatitis) who have a high Ca19-9 value and patients with normal Ca19-9 who have a pancreatic tumor.
  • ductal pancreatic cancer The treatment of ductal pancreatic cancer is currently limited to surgery and chemotherapy.
  • the surgical removal of the tumor offers the only option a chance of recovery.
  • Chemotherapy with the most commonly used chemotherapy Only in a few cases does a life improvement, but no cure. At present, only less than 40% of patients can be treated with curative treatment, and a large proportion of them die on average after 2 years.
  • the typical symptoms of end-stage pancreatic cancer are body wasting and severe pain. Both factors significantly affect the quality of life of patients.
  • pancreatic carcinoma adenocarcinoma .
  • K-ras, DPC4, p53 and p16 seem to play an important role in the development of pancreatic carcinoma (1-4).
  • microarray techniques have also been used to study tumor-specific gene expression in various types of cancers, i.a. also used in pancreatic carcinoma (5-20).
  • Previous studies of tumor-specific gene expression in pancreatic carcinoma were performed with whole tissue samples or with cell lines. In cell lines, however, changes in gene expression can be induced by in vitro conditions that are not present in vivo.
  • Tissue samples from the ductal adenocarcinoma of the pancreas therefore contain various cell types, such as ductal cells, acinar cells, islet cells, inflammatory and nerve cells, as well as fibrocystic elements.
  • the expression profile obtained may represent both the tumor tissue and the adjacent non-neoplastic tissue, making the data obtained questionable.
  • the object of the invention is to provide new methods for the diagnosis and prognosis as well as novel compounds for the treatment of pancreatic carcinoma, in particular of the ductal adenocarcinoma of the pancreas.
  • the object is achieved by a method for in vitro diagnosis of a pancreatic carcinoma, in particular of the ductal adenocarcinoma of the pancreas, wherein the amount of gene product of at least one of the genes listed in Table 1 and / or Table 2 in a sample of biological origin of an individual is determined , The amount of gene product in the sample of biological origin of an individual is compared to the amount of the corresponding gene product commonly present in normal pancreatic epithelial tissue. If it is a gene listed in Table 1, an increased amount of the gene product is an indication of the presence of a gene Pankreaskarzioms. If it is a gene listed in Table 2, a decreased amount of the gene product is an indication of the presence of a pancreatic carcinoma.
  • the invention is based on a study in which it was determined which genes in pancreatic carcinoma undergo an altered expression level compared to the normal pancreatic epithelial tissue. For this purpose, a microdissection of human pancreatic tissue and normal ductal pancreatic epithelial tissue was performed and then a comparative study of gene expression using the U 133 set of Affymetrix (Affymetrix Human Genome U133 Set, Santa Clara, Calif. CA, USA, Order Number: 900444) performed 45,000 Fragments corresponding to 33,000 known genes and 6,000 expressed sequence tags (ESTs).
  • Affymetrix Affymetrix Human Genome U133 Set, Santa Clara, Calif. CA, USA, Order Number: 900444
  • nucleic acid sequences and proteins were identified which undergo an altered expression level in pancreatic carcinoma compared to normal pancreatic epithelial tissue.
  • the altered expression of these genes is causally linked to the pancreatic tumor.
  • pancreatic tumor tissue samples used were homogeneous and do not contain non-neoplastic tissue. Due to the reduced heterogeneity of the microdissected tissue, even the smallest changes in gene expression can be observed.
  • the identification number of the Affymetrix sample set For characterization, the identification number of the Affymetrix sample set, the gene symbol, the gene name, the chromosomal localization, the representative identification number (ID), the identification number of the transcript and that of the corresponding protein are specified (publication numbers in the Entrez database of the National Center for Biotechnology Information (NCBI), Bethesda, USA (http://www.ncbi.nih.gov/entrez/)
  • the q value (in percent) indicates the statistical error with which the evaluation program used predicts differential gene expression.
  • PAK1 interacting protein 1 NM 017906 g8923576 NP 060376 Chr: 6p24.1 4.23644 3.612633
  • Nr Affymetrix Gene Symbol Gene Name Representative Transcript ID Representative Chromosomal FoId q-valve
  • Proteaseome (prosome, NMJ3Q2818 g4506236 NPJ302809 Chr: 14q11.2 2.31359 0.095261 'macropain) activator with 2 (PA28 beta) /// proteasome (prosome, macropain ⁇ activator subunit 2 (PA28 beta) ⁇ >
  • triosephosphate isomerase 1 NM 000365 g4507644 NP 000356 Chr: 12p13 2.12957 1.578435
  • conjuggase folylpoiygammaglutamyl hydrolase
  • gamma-glutamyl hydrolase conjuggase, folylpoiygammaglutamyl hydrolase
  • Table 2 lists genes whose expression in the ductal adenocarcinoma of the pancreas is on average at most half as high as the expression in normal pancreatic epithelial tissue. Ie. the fold change from the expression levels in the microdissected ductal adenocarcinoma of the pancreas (mean over 14 patients) and the expression values in the healthy microdissected ductal pancreas epithelium (mean over 11 persons) is ⁇ 0.5 for these genes the quotient ("fold change") indicated 1000, this means that the gene could be detected only in normal tissue, but not in tumor tissue. The genes are consecutively numbered from the number 541.
  • the identification number of the Affymetrix sample set For characterization, the identification number of the Affymetrix sample set, the gene symbol, the gene name, the chromosomal localization, the representative identification number (ID), the identification number of the transcript and that of the corresponding protein are specified (publication numbers in the Entrez database of the National Center for Biotechnology Information (NCBI), Bethesda, USA (http://www.ncbi.nih.gov/entrez/)
  • the q value (in percent) indicates the statistical error with which the evaluation program used predicts differential gene expression.
  • Oxidase, copper containing 3 vascular adhesion protein 1
  • beta A2 /// NM_005209 g7019356 NP_005200 Chr: 2q34-q36 0.41707 0.095261 crystailin, beta A2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés pour diagnostiquer et pronostiquer un carcinome du pancréas, notamment un adénocarcinome canalaire du pancréas, des procédés pour cribler des substances actives permettant de traiter un carcinome du pancréas, ainsi que l'utilisation de constructions antisens ou de molécules de petit ARN interférent pour produire une composition pharmaceutique permettant de traiter un carcinome du pancréas. Grâce à la comparaison de l'expression génique dans le carcinome du pancréas et dans du tissu épithélial du pancréas normal, au total 1419 gènes exprimés de manière différentielle ont été découverts (650 gènes régulés vers le haut et 769 gènes régulés vers le bas). Il n'était jusqu'alors pas connu que 1267 des 1419 gènes découverts avaient une relation avec une tumeur du pancréas. En déterminant la quantité sur le produit génique d'un tel gène exprimé de manière différentielle dans un échantillon d'origine biologique d'un individu et en la comparant à la quantité sur un produit génique généralement présent dans un tissu du pancréas, il est possible de déterminer l'existence d'un carcinome du pancréas.
PCT/DE2005/001527 2004-08-31 2005-08-26 Composes et procedes pour traiter, diagnostiquer et pronostiquer des maladies pancreatiques WO2006024283A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE112005002742T DE112005002742B4 (de) 2004-08-31 2005-08-26 Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004042822.0 2004-08-31
DE200410042822 DE102004042822A1 (de) 2004-08-31 2004-08-31 Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen

Publications (2)

Publication Number Publication Date
WO2006024283A2 true WO2006024283A2 (fr) 2006-03-09
WO2006024283A3 WO2006024283A3 (fr) 2006-08-31

Family

ID=35853531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2005/001527 WO2006024283A2 (fr) 2004-08-31 2005-08-26 Composes et procedes pour traiter, diagnostiquer et pronostiquer des maladies pancreatiques

Country Status (2)

Country Link
DE (2) DE102004042822A1 (fr)
WO (1) WO2006024283A2 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023840A2 (fr) * 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Marqueurs pronostiques et cibles thérapeutiques s'appliquant au cancer du poumon
WO2008029601A1 (fr) * 2006-08-16 2008-03-13 Forerunner Pharma Research Co., Ltd. Agent thérapeutique cancéreux comprenant un ligand pour la molécule (fm4) du récepteur 2 de neuromédine u en tant qu'ingrédient actif
JP2010539973A (ja) * 2007-10-05 2010-12-24 パシフィック エッジ バイオテクノロジー リミティド 胃腸癌での増殖の徴候及び予後
WO2011151321A1 (fr) * 2010-05-31 2011-12-08 Institut Curie Asf1b, marqueur pronostic et cible thérapeutique du cancer chez l'être humain
EP2463657A1 (fr) * 2010-12-13 2012-06-13 Université de Liège Biomarqueurs, utilisation des biomarqueurs et procédé d'identification des biomarqueurs
JP2013514074A (ja) * 2009-12-17 2013-04-25 ユーシーエル ビジネス ピーエルシー 癌の診断および処置
WO2013016673A3 (fr) * 2011-07-27 2013-05-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation de l'expression de dpep1 et tpx2 pour l'évaluation du traitement ou de la durée de survie de patients atteints d'un adénocarcinome du canal pancréatique
KR20140124601A (ko) * 2013-04-17 2014-10-27 엘지전자 주식회사 췌장암 진단용 바이오마커, 이를 위한 컴퓨팅 장치 및 이의 제어 방법
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
JP2016525883A (ja) * 2013-05-17 2016-09-01 ナショナル ヘルス リサーチ インスティテュートス 腺癌を予後的に分類及び治療する方法
US9433675B2 (en) 2012-05-23 2016-09-06 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2016532856A (ja) * 2013-06-20 2016-10-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 膵臓がんを診断するための方法
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
US9770487B2 (en) 2013-02-20 2017-09-26 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
CN110702923A (zh) * 2019-11-05 2020-01-17 南通大学附属医院 Gpr115基因在制备抗肺癌药物及其诊断试剂盒中的应用
US10782301B2 (en) 2015-02-05 2020-09-22 Queen Mary University Of London Biomarkers for pancreatic cancer
WO2020225426A1 (fr) * 2019-05-08 2020-11-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Examen de dépistage du cancer colorectal et procédé de détection précoce
CN111973744A (zh) * 2020-07-15 2020-11-24 北京大学深圳医院 Plce1-as2在乳腺癌中的应用
CN114480399A (zh) * 2022-03-17 2022-05-13 江苏医药职业学院 降低CPB1基因表达的siRNA、重组载体及其应用
WO2023004460A1 (fr) * 2021-07-28 2023-02-02 Hudson Institute of Medical Research Procédés de détection et/ou de diagnostic du cancer pancréatique
WO2023133275A1 (fr) * 2022-01-07 2023-07-13 Sanford Burnham Prebys Medical Discovery Institute Inhibition de la glutaryl-coa déshydrogénase pour le traitement du mélanome

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020928A2 (fr) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents et procedes permettant d'ameliorer la formation osseuse a l'aide d'oxysterols combines a des proteines morphogeniques osseuses
JP2010133705A (ja) * 2007-03-16 2010-06-17 Perseus Proteomics Inc 癌の診断薬及び治療薬
US9526737B2 (en) 2007-12-03 2016-12-27 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
DE102010043541B4 (de) 2009-12-16 2012-01-26 Technische Universität Dresden Verfahren und Mittel zur Vorhersage der Überlebensdauer beim Pankreaskarzinom durch Analyse von Biomarkern
EP2847206A4 (fr) 2012-05-07 2016-01-20 Univ California Oxy133, un analogue de l'oxystérol, induisant l'ostéo-genèse et la signalisation hedgehog et inhibant l'adipogenèse
US9683009B2 (en) 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046369A2 (fr) * 1999-02-02 2000-08-10 Chiron Corporation Polynucleotides associes a une maladie du pancreas
WO2003078662A1 (fr) * 2002-03-13 2003-09-25 Genomic Health Profilage d'expression genique dans des tissus tumoraux ponctionnes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003260966A1 (en) * 2002-09-30 2004-04-23 Japan As Represented By The President Of The University Of Tokyo Genes and polypeptides relating to human pancreatic cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046369A2 (fr) * 1999-02-02 2000-08-10 Chiron Corporation Polynucleotides associes a une maladie du pancreas
US6429302B1 (en) * 1999-02-02 2002-08-06 Chiron Corporation Polynucleotides related to pancreatic disease
WO2003078662A1 (fr) * 2002-03-13 2003-09-25 Genomic Health Profilage d'expression genique dans des tissus tumoraux ponctionnes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRESS T M ET AL: "A pancreatic cancer-specific expression profile" ONCOGENE, BASINGSTOKE, HANTS, GB, Bd. 13, 1996, Seiten 1819-1830, XP002089888 ISSN: 0950-9232 *
MAITRA A. ET AL.,: "global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays" CLIN. CANCER RESEARCH, Bd. 9, Dezember 2003 (2003-12), Seiten 5988-5995, XP002376207 *
RYU BYUNGWOO ET AL: "Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, Bd. 62, Nr. 3, 1. Februar 2002 (2002-02-01), Seiten 819-826, XP002251739 ISSN: 0008-5472 *
VOZ M.L. ET AL.,: "microarray screening for target genes of the proto-oncogene plag1" ONCOGENE, Bd. 23, 8. Januar 2004 (2004-01-08), Seiten 179-191, XP002376208 *
WERNER S R ET AL: "OVEREXPRESSION OF ONCOGENIC PRL TYROSINE PHOSPHATASES IN HUMAN BREAST, OVARIAN, ENDOMETRIAL, AND PANCREATIC CANCERS" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, Bd. 44, Juli 2003 (2003-07), Seite 1000, XP008032686 ISSN: 0197-016X *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US10174104B2 (en) 2005-11-24 2019-01-08 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10017564B2 (en) 2005-11-24 2018-07-10 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US11739139B2 (en) 2005-11-24 2023-08-29 Astellas Pharma Inc. Monoclonal antibodies against Claudin-18 for treatment of cancer
US10738108B2 (en) 2005-11-24 2020-08-11 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
JPWO2008029601A1 (ja) * 2006-08-16 2010-01-21 株式会社 未来創薬研究所 ニューロメジンｕ受容体２（ｆｍ４）分子に対するリガンドを有効成分として含む癌治療剤
WO2008029601A1 (fr) * 2006-08-16 2008-03-13 Forerunner Pharma Research Co., Ltd. Agent thérapeutique cancéreux comprenant un ligand pour la molécule (fm4) du récepteur 2 de neuromédine u en tant qu'ingrédient actif
WO2008023840A2 (fr) * 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Marqueurs pronostiques et cibles thérapeutiques s'appliquant au cancer du poumon
WO2008023840A3 (fr) * 2006-08-25 2008-07-17 Oncotherapy Science Inc Marqueurs pronostiques et cibles thérapeutiques s'appliquant au cancer du poumon
JP2010539973A (ja) * 2007-10-05 2010-12-24 パシフィック エッジ バイオテクノロジー リミティド 胃腸癌での増殖の徴候及び予後
JP2013514074A (ja) * 2009-12-17 2013-04-25 ユーシーエル ビジネス ピーエルシー 癌の診断および処置
WO2011151321A1 (fr) * 2010-05-31 2011-12-08 Institut Curie Asf1b, marqueur pronostic et cible thérapeutique du cancer chez l'être humain
WO2012079977A1 (fr) * 2010-12-13 2012-06-21 Universite De Liege Biomarqueurs, utilisations de biomarqueurs et procédé d'identification de biomarqueurs
EP2463657A1 (fr) * 2010-12-13 2012-06-13 Université de Liège Biomarqueurs, utilisation des biomarqueurs et procédé d'identification des biomarqueurs
WO2013016673A3 (fr) * 2011-07-27 2013-05-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation de l'expression de dpep1 et tpx2 pour l'évaluation du traitement ou de la durée de survie de patients atteints d'un adénocarcinome du canal pancréatique
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
US11976130B2 (en) 2012-05-09 2024-05-07 Astellas Pharma Inc. Antibodies against claudin 18.2 useful in cancer diagnosis
US10053512B2 (en) 2012-05-09 2018-08-21 Ganymed Pharmaceuticals Ag Antibodies against claudin 18.2 useful in cancer diagnosis
US10022444B2 (en) 2012-05-23 2018-07-17 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10813996B2 (en) 2012-05-23 2020-10-27 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US9433675B2 (en) 2012-05-23 2016-09-06 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US9770487B2 (en) 2013-02-20 2017-09-26 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
US10314890B2 (en) 2013-02-20 2019-06-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
US11826402B2 (en) 2013-02-20 2023-11-28 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
US10946069B2 (en) 2013-02-20 2021-03-16 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US11395852B2 (en) 2013-03-18 2022-07-26 Astellas Pharma Inc. Therapy involving antibodies against Claudin 18.2 for treatment of cancer
KR102058996B1 (ko) 2013-04-17 2019-12-24 엘지전자 주식회사 췌장암 진단용 바이오마커, 이를 위한 컴퓨팅 장치 및 이의 제어 방법
KR20140124601A (ko) * 2013-04-17 2014-10-27 엘지전자 주식회사 췌장암 진단용 바이오마커, 이를 위한 컴퓨팅 장치 및 이의 제어 방법
JP2016525883A (ja) * 2013-05-17 2016-09-01 ナショナル ヘルス リサーチ インスティテュートス 腺癌を予後的に分類及び治療する方法
JP2016532856A (ja) * 2013-06-20 2016-10-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 膵臓がんを診断するための方法
US10782301B2 (en) 2015-02-05 2020-09-22 Queen Mary University Of London Biomarkers for pancreatic cancer
US11977077B2 (en) 2015-02-05 2024-05-07 Queen Mary University Of London Biomarkers for pancreatic cancer
WO2020225426A1 (fr) * 2019-05-08 2020-11-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Examen de dépistage du cancer colorectal et procédé de détection précoce
CN110702923A (zh) * 2019-11-05 2020-01-17 南通大学附属医院 Gpr115基因在制备抗肺癌药物及其诊断试剂盒中的应用
CN111973744A (zh) * 2020-07-15 2020-11-24 北京大学深圳医院 Plce1-as2在乳腺癌中的应用
CN111973744B (zh) * 2020-07-15 2022-07-01 北京大学深圳医院 Plce1-as2在乳腺癌中的应用
WO2023004460A1 (fr) * 2021-07-28 2023-02-02 Hudson Institute of Medical Research Procédés de détection et/ou de diagnostic du cancer pancréatique
WO2023133275A1 (fr) * 2022-01-07 2023-07-13 Sanford Burnham Prebys Medical Discovery Institute Inhibition de la glutaryl-coa déshydrogénase pour le traitement du mélanome
CN114480399A (zh) * 2022-03-17 2022-05-13 江苏医药职业学院 降低CPB1基因表达的siRNA、重组载体及其应用

Also Published As

Publication number Publication date
WO2006024283A3 (fr) 2006-08-31
DE112005002742B4 (de) 2008-05-21
DE112005002742A5 (de) 2007-08-09
DE102004042822A1 (de) 2006-03-16

Similar Documents

Publication Publication Date Title
WO2006024283A2 (fr) Composes et procedes pour traiter, diagnostiquer et pronostiquer des maladies pancreatiques
US20130296185A1 (en) Tape stripping methods for analysis of skin disease and pathological skin state
Zaitseva et al. In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cells
US20110224144A1 (en) Compositions and methods for diagnosing and treating mental disorders
Meola et al. Differentially expressed genes in eutopic and ectopic endometrium of women with endometriosis
EP2504451B1 (fr) Procédés destinés à prédire l'issue clinique d'un cancer
US11591655B2 (en) Diagnostic transcriptomic biomarkers in inflammatory cardiomyopathies
KR101287600B1 (ko) 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
US20070105105A1 (en) Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2021037134A1 (fr) Groupe de gènes du facteur de risque de survie et de typage moléculaire d'un adénocarcinome pulmonaire, produit de diagnostic et application
WO2010129860A2 (fr) Profil d'expression et ciblage de micro-arn dans un tissu pulmonaire atteint d'une bronchopneumopathie chronique obstructive (bpco) et leurs méthodes d'utilisation
US20120289418A1 (en) Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome
US20110190156A1 (en) Molecular signatures for diagnosing scleroderma
Saga et al. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma
Chen et al. Integrative analysis of mRNA and miRNA expression profiles in oral lichen planus: preliminary results
US7879548B2 (en) Detection of biomarkers for neuropsychiatric disorders
Young et al. Microarray analysis of gene expression in human donor sclera
US10106855B2 (en) Genetic assay to determine prognosis in Polycythemia Vera patients
AU2004210986A1 (en) Methods for monitoring drug activities in vivo
Huang et al. Gene expression changes in the human diaphragm after cardiothoracic surgery
US20070134690A1 (en) Diagnosis of systemic onset juvenile idiopathic arthritis through blood leukocyte microarray analysis
CA2531091A1 (fr) Genes regules dans le cancer de l'ovaire utilises comme cibles pronostique et therapeutique
Naciff et al. Uterine temporal response to acute exposure to 17α-ethinyl estradiol in the immature rat
KR101725985B1 (ko) 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
US20040175743A1 (en) Methods for monitoring drug activities in vivo

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1120050027422

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
REF Corresponds to

Ref document number: 112005002742

Country of ref document: DE

Date of ref document: 20070809

Kind code of ref document: P

122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8607

REG Reference to national code

Ref country code: DE

Ref legal event code: 8607